Search

Prompt gamma detection during proton radiotherapy for range verification purposes will need to operate in both active and passive treatment beam environments. This paper describes prompt gamma measurements using a high resolution 2″ × 2″ LaBr3 detector for a 200 MeV clinical passive-scatter proton beam. These measurements examine the most likely discrete prompt gamma rays emitted from tissue by detecting gammas produced in water, Perspex, carbon and liquid-nitrogen targets. Measurements were carried out at several positions around the depth corresponding to the location of the Bragg peak for water and Perspex targets in order to investigate prompt gamma emission as a function of depth along the beam path. This work also focused on validating the Geant4 Monte Carlo model of the passive-scatter proton beam line and LaBr3 detector by making a direct comparison between the simulated and experimental results. The initial prompt gamma measurements were overwhelmed by the high amount of scattered radiation when measuring at isocenter, shifting the target further downstream from the final collimator significantly reduced the background radiation. Prompt gamma peaks were then clearly identified for the water, Perspex and graphite targets. The developed Geant4 Monte Carlo model was able to replicate the measured prompt gamma ray energy spectra, including production for important photopeaks to within 10%, except for the 4.44 MeV peak from the water target, which had more than a 50% overestimation of the number of produced prompt gamma rays. The prompt gamma measurements at various depths correlated well with the proton dose deposition; the 4.44 and 6.13 MeV photopeak profiles peaked within 1 cm of the Bragg peak and the R50% value for the 3–7 MeV energy range predicted the proton range within 8 mm.

Proton radiotherapy has demonstrated benefits in the treatment of certain cancers. Accurate measurements of the proton stopping powers in body tissues are required in order to fully optimise the delivery of such treaments. The PRaVDA Consortium is developing a novel, fully solid state device to measure these stopping powers. The PRaVDA Range Telescope (RT), uses a stack of 24 CMOS Active Pixel Sensors (APS) to measure the residual proton energy after the patient. We present here the ability of the CMOS sensors to detect changes in the signal sizes as the proton traverses the RT, compare the results with theory, and discuss the implications of these results on the reconstruction of proton tracks.

Since the first proof of concept in the early 70s, a number of technologies has been proposed to perform proton CT (pCT), as a means of mapping tissue stopping power for accurate treatment planning in proton therapy. Previous prototypes of energy-range detectors for pCT have been mainly based on the use of scintillator-based calorimeters, to measure proton residual energy after passing through the patient. However, such an approach is limited by the need for only a single proton passing through the energy-range detector in a read-out cycle. A novel approach to this problem could be the use of pixelated detectors, where the independent read-out of each pixel allows to measure simultaneously the residual energy of a number of protons in the same read-out cycle, facilitating a faster and more efficient pCT scan. This paper investigates the suitability of CMOS Active Pixel Sensors (APSs) to track indi- vidual protons as they go through a number of CMOS layers, forming an energy-range telescope. Measurements performed at the iThemba Laboratories will be presented and analysed in terms of correlation, to confirm capability of proton tracking for CMOS APSs.

For many years, silicon micro-strip detectors have been successfully used as tracking detectors for particle and nuclear physics experiments. A new application of this technology is to the field of particle therapy, where radiotherapy is carried out by use of charged particles such as protons or carbon ions. Such a treatment has been shown to have advantages over standard x-ray radiotherapy and as a result of this, many new centres offering particle therapy are currently under construction — including two in the U.K.. The characteristics of a new silicon micro-strip detector based system for this application will be presented. The array uses specifically designed large area sensors in several stations in an x-u-v co-ordinate configuration suitable for very fast proton tracking with minimal ambiguities. The sensors will form a tracker capable of giving information on the path of high energy protons entering and exiting a patient. This will allow proton computed tomography (pCT) to aid the accurate delivery of treatment dose with tuned beam profile and energy. The tracker will also be capable of proton counting and position measurement at the higher fluences and full range of energies used during treatment allowing monitoring of the beam profile and total dose. Results and initial characterisation of sensors will be presented along with details of the proposed readout electronics. Radiation tests and studies with different electronics at the Clatterbridge Cancer Centre and the higher energy proton therapy facility of iThemba LABS in South Africa will also be shown.